

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Hansoh Pharmaceutical Group Company Limited

### 翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

## VOLUNTARY ANNOUNCEMENT

### NEW DRUG APPLICATION OF “IBREXAFUNGERP TABLETS” ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that the New Drug Application of “Ibrexafungerp Tablets” (R&D code: HS-10366), has been accepted by the National Medical Products Administration, and it is intended to be used for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).

As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited\* (翰森(上海)健康科技有限公司) and Jiangsu Hansoh Pharmaceutical Group Company Limited\* (江蘇豪森藥業集團有限公司), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS, Inc. (NASDAQ: SCYX) to research, develop and commercialize Ibrexafungerp in the People’s Republic of China (including Hong Kong, Macau and Taiwan).

#### About Ibrexafungerp

Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has demonstrated broad-spectrum antifungal activity, *in vitro* and *in vivo*, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. As at the date of this announcement, Ibrexafungerp has two indications approved by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis (VVC) and the reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

By Order of the Board  
Hansoh Pharmaceutical Group Company Limited  
Zhong Huijuan  
Chairlady

Hong Kong, July 20, 2023

*As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Ms. Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.*

\* For identification purposes only